-
1 Comment
China Shineway Pharmaceutical Group Limited is currently in a long term uptrend where the price is trading 29.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Finally, its free cash flow grew by 141.1% to $171M since the same quarter in the previous year.
Based on the above factors, China Shineway Pharmaceutical Group Limited gets an overall score of 3/5.
| ISIN | KYG2110P1000 |
|---|---|
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 0.91 |
|---|---|
| Dividend Yield | 6.1% |
| Target Price | None |
| PE Ratio | 9.75 |
| Market Cap | 832M |
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for C1S.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
